Work

Minimal residual disease testing in multiple myeloma by flow cytometry: major heterogeneity

Year: 2013

Type: article

Abstract: To the editor: As more effective therapies become routinely used to treat multiple myeloma,[1][1] standardized methods (such as flow cytometry) to determine the presence/absence of minimal residual disease (MRD) will likely play an increasingly important role in the clinical, research, and

Source: Blood

DOI: 10.1182/blood-2013-05-506170

Authors: Aaron Flanders, Maryalice Stetler-Stevenson, Ola Landgren

Institution: National Cancer Institute

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W2022227828

FWCI: 8.603

Cites: 5

Cited by: 91

Related to: 10